MedTrace Logo

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-08-31

No results posted yet for this study

Summary

This study will determine whether HIV treatment that is initiated during the acute phase of HIV infection, followed by discontinuation of treatment, is effective in reducing the amount of HIV and an increasing the amount of CD4 cells in the blood of people with HIV, compared to the amounts of HIV and CD4 cells in people who do not receive treatment at this stage.

Conditions

  • HIV Infections

Interventions

DRUG

Highly Active Antiretroviral Therapy (HAART)

Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.

OTHER

No treatment

Participants in this group will not receive treatment at this stage of their infection.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Eric S. Rosenberg, MD · Massachusetts General Hospital, Division of Infectious Diseases

  • H.T. Banks, PhD · North Carolina State University, College of Physical and Mathematical Sciences

  • Marie Davidian, PhD · North Carolina State University, Department of Statistics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-02-07
Completion
2017-07-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705926 on ClinicalTrials.gov